| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Sildenafil citrate therapy for pulmonary arterial hypertension.
|
N Engl J Med
|
2005
|
9.27
|
|
2
|
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
|
Circulation
|
2008
|
4.12
|
|
3
|
Tadalafil therapy for pulmonary arterial hypertension.
|
Circulation
|
2009
|
2.98
|
|
4
|
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.
|
Am J Respir Crit Care Med
|
2003
|
2.90
|
|
5
|
Imatinib for the treatment of pulmonary arterial hypertension.
|
N Engl J Med
|
2005
|
2.69
|
|
6
|
Updated evidence-based treatment algorithm in pulmonary arterial hypertension.
|
J Am Coll Cardiol
|
2009
|
2.57
|
|
7
|
Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice.
|
Cell
|
2011
|
2.51
|
|
8
|
Mechanisms of disease: pulmonary arterial hypertension.
|
Nat Rev Cardiol
|
2011
|
2.39
|
|
9
|
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension.
|
Circulation
|
2009
|
2.17
|
|
10
|
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
|
Am J Respir Crit Care Med
|
2014
|
2.16
|
|
11
|
Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+,K+-ATPase.
|
Am J Respir Cell Mol Biol
|
2005
|
1.91
|
|
12
|
Safety and efficacy of exercise training in various forms of pulmonary hypertension.
|
Eur Respir J
|
2012
|
1.83
|
|
13
|
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers.
|
J Am Coll Cardiol
|
2006
|
1.76
|
|
14
|
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
|
J Am Coll Cardiol
|
2008
|
1.69
|
|
15
|
Oleic acid inhibits alveolar fluid reabsorption: a role in acute respiratory distress syndrome?
|
Am J Respir Crit Care Med
|
2004
|
1.66
|
|
16
|
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema.
|
Am J Respir Crit Care Med
|
2014
|
1.48
|
|
17
|
Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension.
|
Am J Respir Crit Care Med
|
2011
|
1.37
|
|
18
|
Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species.
|
Free Radic Biol Med
|
2004
|
1.31
|
|
19
|
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.
|
Chest
|
2011
|
1.29
|
|
20
|
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.
|
Am J Respir Crit Care Med
|
2012
|
1.29
|
|
21
|
Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice.
|
Nat Commun
|
2012
|
1.25
|
|
22
|
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
|
J Am Coll Cardiol
|
2009
|
1.24
|
|
23
|
Targeting non-malignant disorders with tyrosine kinase inhibitors.
|
Nat Rev Drug Discov
|
2010
|
1.24
|
|
24
|
The lectin-like domain of tumor necrosis factor-alpha improves alveolar fluid balance in injured isolated rabbit lungs.
|
Crit Care Med
|
2008
|
1.20
|
|
25
|
Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction.
|
Am J Respir Cell Mol Biol
|
2005
|
1.19
|
|
26
|
Simvastatin as a treatment for pulmonary hypertension trial.
|
Am J Respir Crit Care Med
|
2010
|
1.15
|
|
27
|
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension.
|
Am J Respir Crit Care Med
|
2012
|
1.11
|
|
28
|
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
|
Circulation
|
2008
|
1.10
|
|
29
|
Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.
|
J Am Coll Cardiol
|
2006
|
1.08
|
|
30
|
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.
|
J Heart Lung Transplant
|
2011
|
1.07
|
|
31
|
Fhl-1, a new key protein in pulmonary hypertension.
|
Circulation
|
2008
|
1.03
|
|
32
|
Effects of hypercapnia with and without acidosis on hypoxic pulmonary vasoconstriction.
|
Am J Physiol Lung Cell Mol Physiol
|
2009
|
1.03
|
|
33
|
Effects of mitochondrial inhibitors and uncouplers on hypoxic vasoconstriction in rabbit lungs.
|
Am J Respir Cell Mol Biol
|
2003
|
1.01
|
|
34
|
Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats.
|
Respir Res
|
2011
|
0.92
|
|
35
|
Impairment of respiratory muscle function in pulmonary hypertension.
|
Clin Sci (Lond)
|
2008
|
0.90
|
|
36
|
Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6.
|
Respir Res
|
2011
|
0.90
|
|
37
|
Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
|
Pulm Pharmacol Ther
|
2008
|
0.89
|
|
38
|
Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling.
|
Antioxid Redox Signal
|
2013
|
0.89
|
|
39
|
Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia.
|
Thromb Haemost
|
2005
|
0.88
|
|
40
|
Classical transient receptor potential channel 1 in hypoxia-induced pulmonary hypertension.
|
Am J Respir Crit Care Med
|
2013
|
0.87
|
|
41
|
Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β.
|
Pulm Circ
|
2011
|
0.87
|
|
42
|
Hypoxic pulmonary vasoconstriction--triggered by an increase in reactive oxygen species?
|
Novartis Found Symp
|
2006
|
0.84
|
|
43
|
Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs.
|
Respir Res
|
2007
|
0.84
|
|
44
|
HbA1c in pulmonary arterial hypertension: a marker of prognostic relevance?
|
J Heart Lung Transplant
|
2012
|
0.83
|
|
45
|
Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy.
|
Respir Res
|
2005
|
0.82
|
|
46
|
Effects of hypercapnia and NO synthase inhibition in sustained hypoxic pulmonary vasoconstriction.
|
Respir Res
|
2012
|
0.82
|
|
47
|
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.
|
BMC Pulm Med
|
2010
|
0.82
|
|
48
|
Arterial hypertension in a murine model of sleep apnea: role of NADPH oxidase 2.
|
J Hypertens
|
2014
|
0.82
|
|
49
|
Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.
|
Pulm Circ
|
2013
|
0.82
|
|
50
|
Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis.
|
Respir Res
|
2010
|
0.82
|
|
51
|
Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury.
|
Am J Physiol Lung Cell Mol Physiol
|
2008
|
0.82
|
|
52
|
Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension.
|
Pulm Pharmacol Ther
|
2008
|
0.81
|
|
53
|
Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury.
|
BMC Pulm Med
|
2008
|
0.81
|
|
54
|
Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.
|
Respir Res
|
2011
|
0.81
|
|
55
|
Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
|
Eur J Heart Fail
|
2012
|
0.80
|
|
56
|
Increased neutrophil mediator release in patients with pulmonary hypertension--suppression by inhaled iloprost.
|
Thromb Haemost
|
2003
|
0.80
|
|
57
|
Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension.
|
Ann Intern Med
|
2006
|
0.80
|
|
58
|
Dynamic hyperinflation during exercise in patients with precapillary pulmonary hypertension.
|
Respir Med
|
2011
|
0.80
|
|
59
|
Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function.
|
Respir Physiol Neurobiol
|
2007
|
0.78
|
|
60
|
Pulmonary Hemodynamic Response to Exercise in Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy.
|
Respiration
|
2015
|
0.78
|
|
61
|
Measurement of exhaled hydrogen peroxide from rabbit lungs.
|
Biol Chem
|
2004
|
0.77
|
|
62
|
Cofilin, a hypoxia-regulated protein in murine lungs identified by 2DE: role of the cytoskeletal protein cofilin in pulmonary hypertension.
|
Proteomics
|
2013
|
0.77
|
|
63
|
Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia.
|
Am J Respir Cell Mol Biol
|
2013
|
0.76
|
|
64
|
Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction.
|
Respir Res
|
2010
|
0.76
|
|
65
|
Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension.
|
Pulm Circ
|
2011
|
0.75
|
|
66
|
Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
|
BMC Pulm Med
|
2011
|
0.75
|